The non-Hodgkin’s lymphoma (NHL) therapy market is dominated by patient-share leader rituximab (Roche/Genentech/Chugai Seiyaku/Zenyaku Kogyo’s Rituxan/MabThera). Through 2022, rituximab will maintain its dominance in the face of competition from biosimilars, but novel emerging drug classes will contribute to growth of the overall market. Untapped clinical and commercial potential remains in the NHL market for therapies with improved efficacy and for agents to treat currently underserved NHL subpopulations.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 22 country-specific interviews with thought leaders.
Epidemiology: Diagnosed incidence of follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia/small lymphocytic lymphoma.
Population segments in market forecast: First-line follicular lymphoma, second-line follicular lymphoma, third-line follicular lymphoma; first-line diffuse large B-cell lymphoma, second-line diffuse large B-cell lymphoma, third-line diffuse large B-cell lymphoma; first-line mantle cell lymphoma, second-line mantle cell lymphoma, third-line mantle cell lymphoma; first-line chronic lymphocytic leukemia, second-line chronic lymphocytic leukemia, third-line chronic lymphocytic leukemia.
Emerging therapies: Phase II: 29 drugs; Phase III: 6 drugs; preregistration: 3 drugs.
Alternative market scenario: Launch of Roche/Genentech/AbbVie’s ABT-199 for the treatment of relapsed/refractory chronic lymphocytic leukemia.